BREAKING NEWS

Agency seeks comments on draft guidelines
Findings raise concern about money’s influence on evidence base
Controversial topic gets spotlight at Critical Care Congress
Treatment controls cataplexy in patients with narcolepsy
President-elect takes aim at high drug prices
Drug makers “game” the system, report finds
Phase 2/3 trial evaluates dopamine/norepinephrine reuptake inhibitor

P&T January 2017
Table of Contents

Features

President-elect Donald Trump campaigned on a promise to repeal Obamacare. We review what effect the incoming administration may have on U.S. health care policy.
Health Care & Law
The authors consider market stakeholder consolidation, market-driven efficiency demands, consumerism, and legal enforcement of patient rights related to access to appropriate drugs and posit how future P&T committees may approach these issues.
We examine key evidence against the standard cardiac function model and describe Branko Furst’s alternative model with its implications for therapy and further exploration.
A study finds that medication histories obtained by the pharmacy technician in a busy emergency department were much more accurate than those obtained by nurses.
We present some of the approaches to and challenges of the opioid crisis that emerged from thought-leaders at an Academy of Managed Care Pharmacy symposium.
Meeting Highlights
We review key sessions from the Society for Immunotherapy of Cancer and the American Heart Association annual meetings.

Departments

Medication Errors
Survey reveals widespread health workplace intimidation
Prescription: Washington
Plan to settle 340B disputes is itself the focus of a dispute
Approvals, new indications, regulatory activities, and more
Olaratumab (Lartruvo) for the treatment of soft tissue sarcoma; bezlotoxumab (Zinplava) for use with an antibiotic to reduce recurrence of C. difficile infection; and doxylamine succinate/pyridoxine hydrochloride (Bonjesta) for the treatment of nausea and vomiting during pregnancy
Drug Forecast
Zarxio (filgrastim-sndz), a biosimilar for the treatment of severe chronic neutropenia

P&T TV

How a Texas ACO Corralled Diabetes

Jose F. Peña, MD, head of the Rio Grande Valley ACO, describes impressive results for the organization’s comprehensive program to improve diabetes care and lower related Medicare costs in one of the nation’s poorest areas.

American Diabetes Association 76th Scientific Sessions, June 2016